NCT02962284View on ClinicalTrials.gov

One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

March 31, 2018

Study Completion Date

June 30, 2018

Conditions
Metastatic Prostate Cancer
Interventions
DRUG

abiraterone acetate with Methylprednisolone

YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)

All Listed Sponsors
lead

Sun Pharmaceutical Industries Limited

INDUSTRY

NCT02962284 - One-year, Open Extension to Evaluate the Treatment of Patients With Castration-Resistant Prostate Cancer With YONSA™ | Biotech Hunter | Biotech Hunter